Product Description
IDRX-42, an orally administered small molecule tyrosine kinase inhibitor, is a drug candidate from IDRx for the treatment of Metastatic and/or Unresectable Gastrointestinal Stromal Tumors. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT05489237?term=IDRX-42&draw=2&rank=1)
Mechanisms of Action: TK Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GSK
Company Location: Europe
Company CEO: Emma Walmsley
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Belgium, Brazil, Canada, China, France, Germany, Hungary, Italy, Japan, Korea, Netherlands, Norway, Poland, Romania, South Korea, Spain, Taiwan, United Kingdom, United States, Unknown Location
Active Clinical Trial Count: 5
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Gastrointestinal Cancer|Gastrointestinal Stromal Tumors
Phase 1: Digestive System Cancer|Intestinal Diseases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05489237 |
Study ID: StrateGIST 1 | P1 |
Recruiting |
Gastrointestinal Stromal Tumors|Digestive System Cancer|Intestinal Diseases|Gastrointestinal Cancer |
2027-11-03 |
12% |
2025-11-18 |
|
jRCT2051240255 |
jRCT2051240255 | P1 |
Not yet recruiting |
Gastrointestinal Stromal Tumors |
2027-10-31 |
|||
CTR20230641 |
CTR20230641 | P1 |
Recruiting |
Gastrointestinal Stromal Tumors |
None |
2025-08-13 |
Patient Enrollment|Treatments|Trial Status |
|
jRCT2031250371 |
jRCT2031250371 | P3 |
Not yet recruiting |
Gastrointestinal Stromal Tumors |
2028-10-30 |
|||
NCT07218926 |
StrateGIST 3 | P3 |
Recruiting |
Gastrointestinal Stromal Tumors|Gastrointestinal Cancer |
2028-05-30 |
22% |
2025-12-24 |